A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthrit...

por Cohen, Stanley B., Alten, Rieke, Kameda, Hideto, Hala, Tomas, Radominski, Sebastiao C., Rehman, Muhammad I., Palaparthy, Ramesh, Schumacher, Karl, Schmitt, Susanne, Hua, Steven Y., Ianos, Claudia, Lea Sewell, K.
Publicado 2018

SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations

por Pudelko, Linda, Jaehrling, Frank, Reusch, Christof, Vitri, Sanziago, Stroh, Christopher, Linde, Nina, Sanderson, Michael P., Musch, Doreen, Lebrun, Catherine Jorand, Keil, Marina, Esdar, Christina, Blaukat, Andree, Rosell, Rafael, Schumacher, Karl Maria, Karachaliou, Niki
Publicado 2020

TRLS-03. Intracranial activity of tepotinib in patients with MET exon 14 (METex14) skipping NSCLC enrolled in VISION

por Bestvina, Christine M, Le, Xiuning, Veillon, Remi, Anderson, Ian, Patel, Jyoti, Demedts, Ingel, Garassino, Marina, Mazières, Julien, Morise, Masahiro, Smit, Egbert, Eggleton, S Peter, O’Brate, Aurora, Otto, Gordon, Bruns, Rolf, Schumacher, Karl Maria, Paik, Paul
Publicado 2021

Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study

por Sakai, Hiroshi, Morise, Masahiro, Kato, Terufumi, Matsumoto, Shingo, Sakamoto, Tomohiro, Kumagai, Toru, Tokito, Takaaki, Atagi, Shinji, Kozuki, Toshiyuki, Tanaka, Hiroshi, Chikamori, Kenichi, Shinagawa, Naofumi, Takeoka, Hiroaki, Bruns, Rolf, Straub, Josef, Schumacher, Karl Maria, Paik, Paul K
Publicado 2021

SYST-06 INTRACRANIAL ACTIVITY OF TEPOTINIB IN PATIENTS WITH MET EXON 14 (METEX14) SKIPPING NSCLC ENROLLED IN VISION

por Leighl, Natasha, Bestvina, Christine, Patel, Jyoti, Le, Xiuning, Veillon, Remi, Anderson, Ian, Demedts, Ingel, Garassino, Marina Chiara, Mazières, Julien, Morise, Masahiro, Smit, Egbert, Eggleton, S Peter, O’Brate, Aurora, Otto, Gordon, Bruns, Rolf, Schumacher, Karl Maria, Paik, Paul
Publicado 2022

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

por Le, Xiuning, Sakai, Hiroshi, Felip, Enriqueta, Veillon, Remi, Garassino, Marina Chiara, Raskin, Jo, Cortot, Alexis B., Viteri, Santiago, Mazieres, Julien, Smit, Egbert F., Thomas, Michael, Iams, Wade T., Cho, Byoung Chul, Kim, Hye Ryun, Yang, James Chih-Hsin, Chen, Yuh-Min, Patel, Jyoti D., Bestvina, Christine M., Park, Keunchil, Griesinger, Frank, Johnson, Melissa, Gottfried, Maya, Britschgi, Christian, Heymach, John, Sikoglu, Elif, Berghoff, Karin, Schumacher, Karl-Maria, Bruns, Rolf, Otto, Gordon, Paik, Paul K.
Publicado 2022